Axsome Therapeutics, Inc. $AXSM Shares Bought by Jefferies Financial Group Inc.

Jefferies Financial Group Inc. grew its position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 22.4% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 31,373 shares of the company’s stock after buying an additional 5,745 shares during the quarter. Jefferies Financial Group Inc. owned 0.06% of Axsome Therapeutics worth $5,785,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently bought and sold shares of the company. Machina Capital S.A.S. acquired a new stake in shares of Axsome Therapeutics during the third quarter worth about $632,000. Illinois Municipal Retirement Fund lifted its holdings in Axsome Therapeutics by 72.6% during the 3rd quarter. Illinois Municipal Retirement Fund now owns 13,818 shares of the company’s stock worth $2,548,000 after buying an additional 5,812 shares in the last quarter. Csenge Advisory Group lifted its holdings in Axsome Therapeutics by 24.7% during the 3rd quarter. Csenge Advisory Group now owns 2,577 shares of the company’s stock worth $475,000 after buying an additional 510 shares in the last quarter. New York Life Investment Management LLC purchased a new position in Axsome Therapeutics in the 3rd quarter valued at approximately $1,088,000. Finally, M&G PLC grew its stake in shares of Axsome Therapeutics by 1.2% in the third quarter. M&G PLC now owns 59,697 shares of the company’s stock worth $10,984,000 after acquiring an additional 721 shares in the last quarter. Institutional investors and hedge funds own 81.49% of the company’s stock.

Axsome Therapeutics Price Performance

Shares of NASDAQ:AXSM opened at $144.37 on Friday. Axsome Therapeutics, Inc. has a 12 month low of $123.00 and a 12 month high of $260.19. The firm has a market capitalization of $7.59 billion, a P/E ratio of -47.18 and a beta of 0.86. The company has a debt-to-equity ratio of 1.21, a current ratio of 1.42 and a quick ratio of 1.34. The company’s fifty day moving average price is $172.78 and its 200 day moving average price is $196.98.

Axsome Therapeutics (NASDAQ:AXSM) last released its quarterly earnings data on Monday, November 2nd. The company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.63) by $0.38. The company had revenue of $259.69 million during the quarter, compared to the consensus estimate of $249.19 million. Axsome Therapeutics had a negative net margin of 18.18% and a negative return on equity of 198.73%. Axsome Therapeutics’s revenue for the quarter was up 51.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.94) earnings per share. As a group, sell-side analysts predict that Axsome Therapeutics, Inc. will post -2.27 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms recently issued reports on AXSM. Royal Bank Of Canada decreased their target price on Axsome Therapeutics from $295.00 to $273.00 and set an “outperform” rating for the company in a report on Tuesday, November 3rd. UBS Group dropped their target price on Axsome Therapeutics from $256.00 to $239.00 and set a “buy” rating on the stock in a report on Tuesday, November 3rd. HC Wainwright restated a “buy” rating on shares of Axsome Therapeutics in a research note on Friday, September 25th. Truist Financial raised their price target on Axsome Therapeutics from $200.00 to $285.00 and gave the company a “buy” rating in a research note on Wednesday, September 23rd. Finally, Morgan Stanley lifted their price target on Axsome Therapeutics from $247.00 to $249.00 and gave the stock an “equal weight” rating in a report on Tuesday, November 3rd. One analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Axsome Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $267.58.

Insider Activity

In related news, COO Mark Jacobson sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 3rd. The stock was sold at an average price of $208.65, for a total transaction of $2,086,500.00. Following the transaction, the chief operating officer owned 10,000 shares in the company, valued at $2,086,500. This trade represents a 50.00% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 20.60% of the stock is currently owned by company insiders.

About Axsome Therapeutics

Axsome Therapeutics is a biopharmaceutical company focused on developing and commercializing treatments for central nervous system disorders. The company is headquartered in New York and is led by founder, chairman and chief executive officer Herriot Tabuteau. Its marketed products include Auvelity, an oral treatment for major depressive disorder in adults, and Sunosi, which is used to improve wakefulness in adults with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea.